FDA approves new
formulation of Kaletra

The Food and Drug Administration on Friday approved a tablet form of Abbott Laboratories' protease inhibitor Kaletra. The new tablet formulation does not require refrigeration, as the previous formulation of Kaletra did, and reduces a patient's pill burden from six capsules per day to four tablets. The new Kaletra tablet also can be taken with or without food. Kaletra, which includes a small booster dose of Norvir within the same pill as the drug's other active ingredient, lopinavir, is the world's most commonly prescribed protease inhibitor, according to Abbott officials. (Advocate.com)